Pedro Henrique Zatti

Pedro Henrique Zatti

Auto-generated profile, based on publicly available information

Pedro Henrique Zatti

Universidade de Caxias do Sul

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2022 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
CCCarina Cassini
Carina Cassini
PZPedro Henrique Zatti
Pedro Henrique Zatti
VAValeria Weiss Angeli
Valeria Weiss Angeli
Catia Santos BrancoCatia Santos Branco
Catia Santos Branco
MSMirian Salvador
Mirian Salvador
: Phenolic compounds (PC) have many health benefits such as antioxidant, anticarcinogenic, neuroprotective, and anti-inflammatory activities. All of these activities depend on their chemical structures and their interaction with biological targets in the body. PC occur naturally in polymerized form, linked to glycosides and require metabolic transformation from their ingestion to their absorption. The gut microbiota can transform PC into more easily absorbed metabolites. PC, in turn, have prebiotic and antimicrobial actions on the microbiota. Despite this, their low oral bioavailability still compromises biological performance. Therefore, the use of nanocarriers has been demonstrated to be a useful strategy to improve PC absorption and, consequently, their health effects. Nanotechnology is an excellent alternative able to overcome the limits of oral bioavailability of PC, since it offers protection from degradation during their passage through the gastrointestinal tract. Moreover, nanotechnology is also capable of promoting controlled PC release and modulating the interaction between PC and the microbiota. However, little is known about the impact of nanotechnology on PC effects on the gut microbiota. This review highlights the use of nanotechnology for PC delivery on gut microbiota, focusing on the ability of such formulations to enhance oral bioavailability by applying nanocarriers (polymeric nanoparticles, nanostructured lipid carriers, solid lipid nanoparticles). In addition, the effects of free and nanocarried PC or nanocarriers per se on gut microbiota are also described.

6 June 2022 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
PZPedro Henrique Zatti
Pedro Henrique Zatti
JFJoão Vitor Ferlito
João Vitor Ferlito
Catia Santos BrancoCatia Santos Branco
Catia Santos Branco
Com a chegada do SARS-CoV-2 o mundo se viu em uma guerra contra a doença causada pelo vírus. Essa pode acarretar o comprometimento de sistemas, como do ciclo celular, do estresse, imunológicos e metabólicos, levando ao comprometimento da renina-angiotensina, que está envolvida no funcionamento de órgãos vitais. Paralelamente, se tem um desequilíbrio do sistema redox, desencadeado pela tempestade de citocinas inflamatórias, típica da doença. Esses desequilíbrios são pontos importantes para um pior prognóstico, além da existência de doenças prévias e a idade avançada. Por essas razões, muito se especulou sobre o uso de antioxidantes para prevenção ou combate viral. Neste contexto, a presente revisão sistemática buscou compreender os efeitos dos antioxidantes diante da infecção por SARS-CoV-2. Usando a base de dados Medline/Pubmed, foram explorados dados de estudos clínicos e observacionais retrospectivos e prospectivos, selecionando um total de 25 estudos. O tamanho amostral variou de 12 a 4314 indivíduos e a idade média foi de 55,27 ± 11,82. A maioria dos estudos utilizou a vitamina D (n=10) como intervenção, seguido pela vitamina C (n=6), zinco (n=5) e compostos fenólicos (n=4). Quanto a avaliação da qualidade dos estudos, foi encontrado um escore médio de 7,38 pontos para estudos clínicos e 9,28 pontos para estudos observacionais, indicando boa qualidade metodológica. Apesar de haver algumas evidências que apontam para os benefícios do uso de antioxidantes frente à doença, ainda não é possível se ter um consenso sobre seu real papel, motivo dado pela heterogeneidade dos estudos e a discrepância entre os resultados publicados.

1 July 2022 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
PMPaulina Ampessan Maccari
Paulina Ampessan Maccari
AVAna Paula Vargas Visentin
Ana Paula Vargas Visentin
PZPedro Henrique Zatti
Pedro Henrique Zatti
MSMirian Salvador
Mirian Salvador
Catia Santos BrancoCatia Santos Branco
Catia Santos Branco
Depression is considered a public health problem and is one of the main causes of professional or social disability worldwide. Antioxidants are substances known for their preventive or therapeutic effects on various diseases, including depression. These benefits can be explained by the inherent ability of these molecules to modulate cell signaling pathways. This study aimed to evaluate the neuroprotective effects of resveratrol in an in vitro model of depression. Experimental studies were performed with U-87 MG glial cells derived from the human brain lineage. Different concentrations of resveratrol were used in the presence or absence of kynurenine, a metabolite of the amino acid tryptophan necessary for the synthesis of serotonin. Cell viability was evaluated by determining the ability of cells to reduce the MTT compound (3-[4,5-dimethylthiazol 2-yl]-2,5-diphenyltetrazoline bromide), in addition to cell morphological evaluation. To assess the level of oxidative stress, treated glial cells were subjected to the TBARS test to quantify lipid peroxidation. Kynurenine doses of 100 and 200 µM were cytotoxic, reducing glial cell viability and altering cell morphology. This reduction was accompanied by increased oxidative damage to lipids. Resveratrol (10 µM) was shown to be preventive in maintaining the viability of glial cells when treated with 100 µM kynurenine. The results may contribute to the understanding of the mechanisms involved in depression, contributing to the new focus on the ability of polyphenols, compounds naturally found in the diet, to become adjuvant therapeutic agents for the treatment of neuropsychiatric disorders.